In FSGS, podocytes are damaged, like a net with torn holes, allowing protein to leak into the urine, creating a harmful ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® ...

Fintel reports that on November 4, 2025, Piper Sandler maintained coverage of Travere Therapeutics (NasdaqGM:TVTX) with a ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

Discover key Q3 2025 earnings insights for Travere Therapeutics, including FILSPARI sales growth, FDA milestones, and outlook for rare kidney ...

Travere Therapeutics (TVTX) is scheduled to announce Q3 earnings results on Thursday, October 30th, after market close. The consensus EPS Estimate is -$0.09 (+8 ...

Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit. The stock rose 14% to $33.67, and at one point touched a new 52-week high of ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ:TVTX) reported third-quarter earnings that significantly exceeded analyst expectations, driven by robust sales growth of its kidney disease ...

Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics, Inc.